Connect with us

Entrepreneur

Could the first instant at-home test transform how women track their hormones?

Published

on

Eli Health is on a mission to transform female hormone testing with the first FDA-registered instant hormone monitoring system. Co-founder and CEO, Marina Pavlovic Rivas, speaks to Femtech World about making hormone testing more accessible.

The Hormometer, developed by femtech company, Eli Health, enables real-time, saliva testing for instant results, enabling women to monitor their hormonal fluctuations from the comfort of their own home.

Developed over five years, Eli Health raised US$12m in its Series A funding to scale the product, bringing its total funding to US$20m. 

The FDA-registered Hormometer is an at-home needle-free test kit that utilises AI for data-driven insights. Currently, the Hormometer enables women to test their progesterone and cortisol levels, with estradiol testing currently in development.

While women have traditionally paid hundreds of pounds for tests, potentially waiting weeks for test results, Eli’s Hormometer uses computer vision algorithms to analyse the saliva samples, delivering results in 20 minutes at around UD$8 per test.

Marina Pavlovic Rivas, co-founder and CEO of Eli Health, which has 12 patented inventions for hormone monitoring, says that the tests and accompanying app offer insights into women’s health across fertility, menopause, and mental health, enabling improved access and affordability to hormone testing.

“We started the company because we wanted women to have access to the important data when it comes to their health,” Rivas tells Femtech World.

“We realised that when it comes to hormones, this data doesn’t exist at the frequency it’s needed, because you can test your hormones through a lab, but that process takes at best a few days, and on average, a few weeks. It is quite expensive as well.”

Traditional hormone lab tests only provide insight into a certain window of time, Rivas explains, but for women, whose hormones are in constant fluctuation, more consistent monitoring is needed. Hormones like cortisol can also fluctuate up to 100 per cent in one hour, making it difficult to get a full picture. 

“This frequency and cost don’t enable high frequency, long-term testing, which reflects, ultimately, the fluctuations of hormones that happen on a daily basis,” Rivas says.

“Our mission became to create that real-time interface for the human body, so that we can have access to this data at the frequency that matters.”

Using lateral flow assays, the test works by collecting saliva from the tongue. The individual then uploads a picture of the test into the app. 

The app utilises AI-driven insights to provide lab-grade results on hormone levels, along with scores, benchmarks and recommendations to enable women to take action.

“What we enable is not just cheaper, faster testing,” says Rivas. “It’s a very different approach to this type of data. Let’s say you’re measuring your heart rate at the doctor’s office once per year, it’s very different to having it on your wrist at all times with a smart watch. That becomes information that you can use on a daily basis to take actions around your lifestyle, for example, sleep, exercise, and all areas of your health and wellness.”

Explaining the range of markers measured by the Hormometre, she continues: “It touches the typical areas of women’s health – fertility and menopause, but also endocrine conditions and beyond that, some of our hormones, like cortisol, are not reproductive hormones. For us, it was important to include them, because when we speak of hormonal health, it goes beyond reproductive health.

“Some biomarkers like cortisol have a major impact on mental health, how people feel on a daily basis, how they perform at work, but also when they exercise and ultimately, all aspects of their health. It is our mission to enable people to improve their health and performance across all of those different areas.”

Rivas adds: “Around 80 per cent of women will experience symptoms related to hormonal imbalances in their lives, so that’s a very high number of people. When it comes to some hormones like cortisol, there’s one in three people who experience dysregulation. 

“How that translates on a day-to-day basis is that people live with different symptoms that impact their work, that impact personal lives, and having that information enables them to manage those symptoms and even eliminate them.”

It is not only about monitoring hormones, as Rivas highlights, but also about taking preventative action to ward off potential chronic conditions in the future.

“It has been shown in research again and again that dysregulation of some hormones, like cortisol, is also linked to higher probability of developing different conditions, including chronic conditions, heart conditions, cognitive disease and more,” says Rivas.

“Tracking hormones has the double benefit of feeling better today, but also preventing different conditions tomorrow.”

Having recently won the Femtech World Brain and Mental Health Innovation award for its work to help women better understand the impact of hormones on their mental health, EliHealth is now focusing on expanding to other markers.

“We are always focused on making a product that can address the needs of our users, and we’re always very focused on that work. So, to be able to take a step back and have recognition from the industry is meaningful for us in our mission,” Rivas adds.

“The future will be about continuing to focus on that mission of making a real-time interface to the human body by expanding to other hormones and their markers, and ultimately providing that information in real time to our users.”

Eli Health won the Brain and Mental Health Innovation category at the Femtech World Awards 2025. See full winners list here

Entrepreneur

Women’s Health Innovation Summit opens submissions for 2026 Innovation Showcase

Published

on

The Women’s Health Innovation Summit (WHIS) has announced that submissions are  open for the 2026 Innovation Showcase, giving early and growth-stage start-ups the  chance to present their solutions to the most influential audience in women’s health.

Taking place October 13–15 at Encore Boston Harbor in Everett, Massachusetts, WHIS  brings together more than 1,000 decision-makers from across the women’s health  ecosystem — investors, payers, health systems, pharma leaders, and employers — all  under one roof.

Selected companies will pitch live on stage to an audience with the funding, expertise,  and connections to accelerate their growth.

Past participants have walked away with  investor introductions, commercial partnerships, and clinical collaborations that  moved from conversation to contract.

WHIS is where the women’s health ecosystem comes together to get deals done,” said Sarah Rowlands, marketing director.

“The Innovation Showcase puts promising start ups directly in front of the people who can take them to the next level.”

The showcase sits at the heart of a three-day programme spanning digital health,  therapeutics, diagnostics, and consumer health.

Previous attendees have included  representatives from Mayo Clinic, CVS Health, Eli Lilly, Brigham and Women’s Hospital,  Alumni Ventures, Muse Capital, and Maverick Ventures, among hundreds of others.

Applications are open now. Start-ups can submit at

www.whisusa.com/attend/start-ups

About WHIS

Now in its eighth year, the Women’s Health Innovation Summit is the largest global  gathering of senior leaders shaping the future of women’s health.

Organised by Kisaco  Research, WHIS unites providers, health plans, employers, regulators, pharma,  investors, and innovators to increase deal flow, expand reimbursement, improve  access, and deliver better health outcomes for women at every stage of life.

WHIS 2026 takes place October 13–15 at Encore Boston Harbor, Everett, MA.

Learn more at www.whisusa.com

Continue Reading

News

Five women-led startups selected for Imperial pre-accelerator

Published

on

Five women-led startups will compete for a share of a £30,000 prize fund in Imperial’s WE Innovate final on Monday 15 June 2026.

The finalists are building businesses to tackle challenges in areas including vaccine technology, epilepsy care and the destruction of “forever chemicals”.

The WE Innovate programme, run by Imperial Enterprise Lab, is a targeted pre-accelerator open to teams led by students, recent alumni and early career researchers who identify as women.

The programme supports 25 women-led teams through six months of masterclasses, business coaching, one-to-one expert support and peer mentoring.

The top five teams will compete to win a share of the £30,000 prize fund at the WE Innovate Grand Final Showcase at Imperial on Monday 15 June 2026 from 18:00 to 21:00.

Tickets are free and available on a first-come, first-served basis.

This year’s final also marks the second year of WE Innovate National, a growing UK-wide programme that has expanded the WE Innovate model built at Imperial to other parts of the country.

Alongside Imperial, Queen’s University Belfast, Swansea University and Loughborough University are each hosting their own grand final showcases on their campuses.

The four showcases are collectively contributing to a shared national ecosystem focused on supporting women-led innovation.

WE Innovate National is set to expand to seven universities next year, supporting 175 women-led startup teams across the UK.

AlphaVectors Biotech is developing a lipid nanoparticle platform to enhance the stability of RNA vaccines at room temperatures.

Lipid nanoparticles are tiny fat-based particles used to deliver genetic medicines into the body. RNA vaccines use genetic instructions to help the immune system recognise a disease target.

Current RNA-based therapeutics rely on lipid nanoparticles that need storage at between -20°C and -80°C and high dosing. This increases distribution costs and leads to significant wastage, limiting scalability, deployment and accessibility in lower-resource markets.

AlphaVectors Biotech says its technology can lower the need for temperature-controlled supply chains, reduce costs and improve the scalability of RNA vaccines for wider deployment.

The startup is led by Dr Apanpreet Kaur, an Imperial alumnus with a PhD in chemical engineering.

Epile-X, by NeuraVance Labs, is working on a platform that could provide continuous, real-world brain monitoring for people with epilepsy.

More than 630,000 people in the UK live with epilepsy, according to the charity Epilepsy Action.

Epilepsy is a neurological condition that can cause recurring seizures. EEG, or electroencephalography, is a test that records electrical activity in the brain.

Current diagnosis relies on EEG recordings in clinical settings and patient-reported diaries, which may miss seizures that happen during daily life.

The startup says its technology combines a wearable EEG with AI-driven analysis to capture daily brain activity and support improved diagnosis and more personalised treatment decisions.

Epile-X is led by Ester D’Alterio, an innovation, entrepreneurship and management MSc graduate from Imperial.

FluoroCycle is developing technology for low-energy chemical destruction of PFAS, breaking down “forever chemicals” at 10 times lower temperatures than current incineration methods.

PFAS are synthetic chemicals found in air, water and soil. Some studies have linked exposure to them to health risks including thyroid disease, reproductive illness and cancer.

The startup aims to make PFAS destruction more affordable by providing its technology as an onsite engineered unit, allowing customers to save on energy and transport costs while cutting their carbon footprint.

FluoroCycle is led by Amanda Fogh, a research associate in Imperial’s department of chemistry.

Waypoint is building a video game controller for visually impaired players to hear and feel popular games, including Super Mario and Minecraft.

At least 2.2 billion people globally have some form of vision impairment, according to the World Health Organisation, while estimates show around 43 million people have complete blindness.

Waypoint says only 0.001 per cent of video games are fully playable for blind gamers.

The startup’s technology uses computer vision and AI to read the game screen and translate key information into sound, vibration and touch for a fully immersive experience.

The founders say it is the first game controller designed to make video games fully playable for blind players.

Waypoint is led by Bana Quronfuleh, an innovation design engineering MSc student at Imperial.

Snitch is developing an accountability-based app that allows friends to cut down their screen time together.

UK adults spend an average of 4.5 hours a day online on personal smartphones, tablets and computers, according to Ofcom’s Online Nation 2025 report.

Young adults spend more than six hours online on average. Some research suggests excessive screen use may have a negative impact on mental and physical health.

The app allows users to join accountability groups and set shared limits across their most used apps.

When one person scrolls, the group’s combined timer counts down. The founders say this helps build awareness, encourage reflection and create small behavioural shifts by making screen use a shared responsibility.

Snitch is led by Asha Bakhai, a design engineering MEng graduate from Imperial.

Continue Reading

News

Sun Pharma to acquire Organon in US$11bn deal

Published

on

Indian pharmaceutical giant Sun Pharma has agreed to buy Organon for US$11.75bn in a deal aimed at expanding its women’s health and biosimilars business.

Organon, which was spun out of Merck in 2021, has built a portfolio of more than 70 women’s health and general medicines products, including biosimilars, sold in the US and about 140 other countries.

The acquisition would give Sun Pharma a broader presence in biosimilars, which are medicines designed to be highly similar to existing biological drugs, and strengthen its position in women’s health.

Dilip Shanghvi, executive chairman of Sun Pharma, said: “Organon’s portfolio, capabilities, and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.”

The companies said the combined business would generate annual revenue of US$12.4bn, operate across 150 countries and rank among the top three companies globally in women’s health.

They also said it would become the seventh largest biosimilar player.

Sun Pharma said the deal would help grow its innovative medicines business and expand its biosimilars offering.

It added that the combined company would have 18 large markets each generating more than US$100m in revenue.

Organon’s largest markets include the US, Brazil, Canada, China and countries in the European Union. The company also has six manufacturing facilities across the EU and emerging markets.

The deal follows market speculation that began on 10 April, when Indian media reported that Sun Pharma had submitted an all-cash offer for Organon.

A later report said the offer had been revised to US$13bn. Sun Pharma shares rose about 7 per cent on India’s National Stock Exchange after the announcement.

Sun Pharma said it would acquire all of Organon’s issued and outstanding shares in cash, using a combination of available cash and committed bank financing. It also estimated synergies of about US$350m within two to four years of completion.

The company said the acquisition would strengthen its cash generation, with EBITDA and cash flow set to nearly double, supporting efforts to reduce the net debt to EBITDA ratio of 2.3 times resulting from the deal. EBITDA is a measure of operating performance before certain costs are deducted.

Organon reported revenue of US$6.2bn last year and adjusted EBITDA of US$1.9bn. It also reported debt of US$8.64bn, down from US$9.5bn when it separated from Merck, and a cash balance of US$574m.

In November, Organon announced plans to sell its JADA System, designed to control and treat abnormal postpartum uterine bleeding or haemorrhage, to Laborie Medical Technologies for up to US$465m. Net proceeds from the sale will contribute to Organon’s cash balance as of 31 March 2026.

Organon will merge with a subsidiary of Sun Pharma, with Organon surviving the merger. The boards of both companies have approved the transaction.

Carrie Cox, executive chair of Organon, said: “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders.”

The transaction is expected to close in early 2027, subject to regulatory approvals and Organon stockholder approval.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.